Calypte Only Company with Full Menu of Tests.

Jetzt beginnt die Massenflucht aus der Aktie.
Tief war schon bei 0,23$

Open 0.27
Previous Close 0.25
Exchange of Last Sale Amex
Time of Last Sale 09:57:25
      Tick        Up§
       Bid      0.24§
       Ask§
Size Bid/Ask 298x3350
Symbol Type Equity

Fundamental Data Table
52 Week High 0.35
52 Week Low 0.13
       EPS§-0.05
P/E Ratio 0.00
Shares Outstanding 203,000,000
Market Cap 50,684,000
      Beta§1.036
Dividend Frequency
Ex-Dividend Date
Dividend Amount
     Yield§0.00
Primary Exchange Ame


Grüße, ZN

Time & Sales most recent  next page
Rec. Time Action Price Volume
10:03:42 AM Bid 0.23  249500  
10:03:32 AM Bid 0.23  248500  
10:01:54 AM Bid 0.23  249500  
10:01:44 AM Bid 0.23  248500  
10:01:36 AM Ask 0.24  28100  
10:01:32 AM Trade 0.24  2000  
10:01:32 AM Bid 0.23  249500  
10:01:24 AM Trade 0.24  10000  
10:01:22 AM Trade 0.24  10000  
10:00:40 AM Trade 0.24  10000  
10:00:40 AM Bid 0.24  10000  
10:00:24 AM Trade 0.24  2000  
10:00:24 AM Trade 0.24  5000  
10:00:24 AM Trade 0.24  100  
10:00:24 AM Trade 0.24  100  
10:00:24 AM Trade 0.24  100  
10:00:24 AM Trade 0.24  100  
10:00:24 AM Trade 0.24  5000  
10:00:24 AM Bid 0.24  2000  
9:59:14 AM Ask 0.25  458000  
9:58:36 AM Bid 0.24  12400  
9:58:22 AM Trade 0.24  5100  

ich sage dazu nur: immer noch 0,24 X 181.000.000 = 43.440.000-$-mk für ein bude mit einem jahresumsatz von 427.000$ und einem verlust der mehr als 20-fach so hoch ist....

AMEN

verkauft, tun es die anderen "für euch"

Time & Sales most recent  next page
Rec. Time Action Price Volume
10:36:38 AM Trade 0.23  16500  
10:36:06 AM Trade 0.24  200  
10:36:06 AM Trade 0.24  100  
10:36:06 AM Trade 0.24  100  
10:36:06 AM Trade 0.24  100  
10:36:04 AM Trade 0.24  100  
10:35:44 AM Bid 0.23  252500  
10:35:42 AM Trade 0.24  400  
10:35:38 AM Bid 0.23  251500  
10:35:26 AM Trade 0.23  5000  
10:35:26 AM Bid 0.23  252500  
10:35:02 AM Trade 0.23  1000  
10:34:20 AM Bid 0.23  257500  
10:34:10 AM Ask 0.24  40000  
10:34:06 AM Trade 0.24  1000  
10:33:56 AM Bid 0.23  256500  
10:33:52 AM Bid 0.23  255500  
10:33:36 AM Ask 0.24  41000  
10:33:34 AM Trade 0.24  1000  
10:33:06 AM Ask 0.24  42000  
10:33:02 AM Trade 0.24  1000  
10:32:58 AM Ask 0.24  43000  

OK ich habs kapiert, ein Fehlinvest in euren Augen, akzeptiert.
Was dazu führt das ihr Oberwasser habt!. akzeptiert.
Joelu kümmert sich nicht um seine eigenen Investments, akzeptiert.

Trotzdem möchte ich auch meinen Standpunkt hier guttun, akzeptiert?

1.Vor einer Woche schreibt hier Joelu wie ein Besessener Calypte fliegt nächste Woche aus der AMEX. Das ist nicht passiert!!!!!!!!!!!!!!!!!!!!!!!!!!!!.
2.Joelu schrieb immer, mit 15 Mitarbeiter kann Calypte keine Rapidtests produzieren.
Diese Woche meldet Calypte das 51% einer Manifaktur besitzen, um Ergo Tests zu produzieren.
3. Marr hat Calypte eine Kreditlinie von 2.000.000 $ zugesichert.
4. Bezogen auf die aktuelle Cashsituation Stand 31.12.05 was die 475000$.
5. Die Manifaktur wird 10.000.000 Tests pro Monat produzieren.
6. Calypte wird eine Zulassung in den USA beantragen.
7. Verkaufspreis je Test 1,60$
8. Marge 42% pro Test.
9. Calypte wird, ja wird die Zulassung von China bekommen.
10. OTC- Verkäufe aus Dubai werden 2006 auch kommen.
11. Trinity hat keinen Speicheschnelltest.
12.Osur Speicheltest ist teuerer und schlechter als der von Caly.
13.und der wichtigste Punkt Joelu und Kade... die AMEX hat bestimmt nicht auf Grund der bisher veröffentlichen "NEWS" Calypte die Frist eingeräumt.
14. Ich bin mittlerweilen Schmerzfrei was den Kurs anbelangt, ob er jetzt bei 0,35 oder 0,20 steht.
15. Wenn ihr die Marge ausrechnet, bei 120.000.000 Test und dann Berechnung anstellt wird Caly einen Kurs von min. 10$ haben.
16. Fokusierung von Caly ist China-Russland-Asien und Afrika demnächst  Beantragung der Zulassung von Speichelschnelltests in USA.
17. Ich bin und war immer einer derjenigen die nach vorne schauen und die Entwicklung betrachtet und nicht die Vergangenheit.
18.Marr hat das Zepter in der Hand und die Marrgroup will und wird mit Calypte Geld verdienen.
19. Basher wird es immer geben ,akzeptiert.
20. Eins nach dem anderen.
Im diesen Sinne mein Lieben,Lucky

Trinity Biotech plc         o Uni-Gold            o Uni-Gold is the number two selling HIV rapid test
                                                   behind Determine in Africa
--------------------------- --------------------- --------------------------------------------------
OraSure Technologies Inc.   o OraQuick            o Only other company to offer alternative fluid
                           o OraQuick Advance      rapid tests
--------------------------- --------------------- --------------------------------------------------
ChemBio Diagnostics, Inc.   o Sure Check HIV      o Established sales offices in Tanzania and Nigeria
                           o HIV 1/2 Stat Pak    o Offers quality "western products" at low price
                                                   point
--------------------------- --------------------- --------------------------------------------------

product.  In the fourth  quarter of 2005, we introduced a new version of the BED
incidence test that permits the use of dried blood spot samples,  an alternative
to the whole blood  samples  initially  required for the test.  Dried blood spot
sampling has a long history in HIV testing and has  advantages  over whole blood
samples,  including ease of collection through fingersticks,  no requirement for
refrigerated  sample  shipping,  and the ability to archive the sample on filter
paper. We believe that this alternative  sample will further increase the market
for our BED incidence test.


                                      32



Third  quarter  2005  revenue from the sale of this test grew by 86% compared to
sales in the second quarter, but sales decreased by 30% in the fourth quarter of
2005  compared  with the third  quarter.  In  February  2006,  the CDC issued an
Information  Sheet:  Using the BED HIV-1 Capture EIA Assay to Estimate Incidence
Using STARHS in the Context of  Surveillance  in the U.S.  addressing a December
2005 UNAIDS report regarding studies in Africa and Thailand  indicating that the
Incidence Test  apparently  over-estimated  the incidence  rate. The Information
Sheet  acknowledges  that the  assay  may cause  over-estimation  under  certain
conditions and suggests  expanding current  protocols.  We see the test's design
and use and the interpretation of its results evolving as public health agencies
and the CDC gains  experience with it. We continue to believe that the Incidence
Test is a valuable  technology  in the fight  against the spread of HIV/AIDS and
that it will remain a viable  epidemiological  surveillance test. We expect that
the process of refining its applications will continue as its use expands.

Further,  we have begun the research on a blood-based  rapid HIV incidence  test
for  diagnostic  and  surveillance  purposes  under the  terms of a  Cooperative
Research  and  Development  Agreement  (CRADA) with the CDC. We plan to file the
appropriate  IDE  applications  with the US FDA for  diagnostic  versions of the
incidence test.

Rapid Tests We expect that our future  revenues will be derived  primarily  from
the sale of our HIV-1/2  rapid  diagnostic  tests both to the  professional  and
over-the-counter  (OTC) markets,  and  potentially  from the sales of diagnostic
tests for other STDs. Our focus for 2006 is concentrated on commercializing  the
HIV-1/2 rapid tests,  initially in a  dipstick-format  and produced in Thailand,
from which we believe we can source certain African and southeast Asian markets.
We plan to supply the Chinese market with product manufactured locally,  through
our Chinese subsidiary, Beijing Marr. In all markets, commencement of rapid test
sales is contingent  upon the successful  completion of clinical trials followed
by  the  required  regulatory  approvals,  coupled  with  successful  technology
transfer and scale-up of manufacturing  operations. We do not expect significant
revenues  from the sale of our rapid tests in 2006 as we are in the early stages
of the regulatory  process with many of our initial target markets in Africa and
Asia.

In China, we have completed the clinical trials on our HIV rapid tests that were
conducted by the  National  Center for AIDS/STD  Control and  Prevention  of the
Chinese CDC. The trials  involved  approximately  1,500  subjects.  Based on the
results of the trials,  we believe  that the  performance  of both our blood and
oral fluid rapid tests was sufficient to make them approvable.

Since the SFDA expressed an interest in alternative fluid testing, we decided to
initially submit only our oral fluid HIV-1/2 test for approval. We submitted our
application  for  approval  in late  2005  and  were  informed  that it had been
formally  accepted for  evaluation  in early 2006.  Like the U.S.  Food and Drug
Administration,  the  SFDA  has a  statutory  limitation  on  responding  to our
submission.  We do not know at this time whether the initial response will be an
approval  or a request  for more  information.  In the  United  States,  this is
usually an iterative process.

Beijing Marr will manage the Chinese oral fluid test product  launch.  There are
several large markets in China,  such as those created by new laws requiring the
testing of military recruits and university students as part of their admissions
process, as well as a publicly-announced commitment by the Chinese government to
offer voluntary HIV testing to its entire 1.36 billion person  population.  With
trained  non-professionals  and a safe,  non-invasive oral fluid test, we expect
strong demand for our initial test.

Beijing  Marr's  acquisition  of the  Yaohua  Assets  provides  us not only with
manufacturing  facilities  to produce  our rapid  tests in China,  but also with
certain rights to technology and governmental  approvals and certifications that
we  expect  will  significantly   reduce  our  projected  time  to  market.  Our
manufacturing  equipment  and personnel are on-site and we are in the process of
transferring  our  technology,  renovating  and  preparing  the  facilities  for
production and completing the transfer of the Yaohua Assets in  anticipation  of
the approval of our AwareTM  HIV-1/2 rapid oral fluid (OMT)  diagnostic  test by
the SFDA. The renovations we are making to the facilities are required for us to
renew our GMP  certification,  which  will  otherwise  expire in June  2006.  We
anticipate  completion of these  renovations in sufficient time to meet the June
renewal date of our GMP certificate.

Because of the long and  uncertain  process of SFDA  evaluation of our products,
and because the Yaohua Assets include a blood rapid HIV-1/2 test that is already
approved by the SFDA,  we elected not to proceed with a submission  of our Aware
BSP HIV-1/2  test at this time.  If we determine  to  manufacture  a blood rapid
HIV-1/2  test,  we will  consider  manufacturing  the blood rapid  HIV-1/2  test
acquired as part of the Yaohua Assets.


                                      33



We also  developed  a urine  rapid test that was  designed  to provide  the same
functionality  as the oral fluid  test and that was  subjected  to the  clinical
trial  evaluation.  Although  the results of the Chinese  trial on that test may
have been  sufficient to make it  approvable,  it did not  demonstrate  the same
level of  accuracy  as either the  blood/serum/plasma  (BSP) or oral fluid (OMT)
tests in that or other recent evaluations. Accordingly, we have decided to place
the urine test back into development to further  optimize its performance.  As a
result of current  resource  constraints,  the optimization of the urine test is
not an active project.

We have completed the regulatory approval process for our Aware HIV-1/2 BSP test
in  South  Africa  and  Kenya,  as well as other  clinical  trials  and  product
registrations. We are in the process of evaluating registration requirements for
our rapid tests in India with the  objective of commencing  product  evaluations
for certain  markets there. We have begun to develop  distribution  channels and
plan to conduct  additional  trials in several African  countries.  The clinical
trial  and  regulatory  approval  process  will be  on-going  as we  attempt  to
introduce the Aware HIV-1/2 tests  internationally.  We are primarily  targeting
countries  which have been  selected  for  funding by  PEPFAR,  the $15  billion
President's Emergency Plan for AIDS Relief, and currently have representation in
more than half of them.  While there are  different  regulations  and customs in
each  foreign  country,  we believe  that the  regulatory  process in the PEPFAR
countries can generally be completed within a few months.

Many HIV intervention  programs in developing countries are supported by foreign
funding. In the case of funding from the United States, typically through PEPFAR
or USAID,  products  that are not  approved  locally or by the USFDA may be used
provided  they have a waiver issued by the USAID and CDC. It is our intention to
pursue a USAID waiver shortly,  initially for our Aware HIV-1/2 OMT test. We are
compiling the required data in terms of "manufacturer's  claims" and independent
trials for the blood,  serum and plasma tests. We believe that obtaining a USAID
waiver is an important  milestone  in  facilitating  international  sales of our
rapid tests.

Last:

0.24  hiv - CALYPTE BIOMEDICAL CORP
Change:

-0.04  % Change:

-14.29%  High:

0.27  Low:

0.23  Volume:

2,370,000  

Price Data Table  
Open 0.27  
Previous Close 0.24  
Exchange of Last Sale Amex  
Time of Last Sale 16:00:16  
Tick Unchanged  
Bid 0.2  
Ask  
Size Bid/Ask 20x30  
Symbol Type Equity